Coherus Oncology (CHRS) Inventory (2018 - 2026)

Coherus Oncology (CHRS) has 9 years of Inventory data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 37.15% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 37.15% YoY), and the FY2025 full-year result was $3.2 million, down 24.6% from the prior year.
• Inventory improved to $4.8 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $66.8 million in Q3 2023 to a low of $2.0 million in Q3 2025.
• A 5-year average of $33.6 million and a median of $36.9 million in 2022 frame the typical range for Inventory.
• Across the five-year window, Inventory surged 140.93% in 2023 and sank 95.7% in 2025, its largest moves.
• Tracing CHRS's Inventory over 5 years: stood at $38.8 million in 2022, then surged by 61.39% to $62.6 million in 2023, then plunged by 93.28% to $4.2 million in 2024, then fell by 24.6% to $3.2 million in 2025, then surged by 52.11% to $4.8 million in 2026.
• Business Quant data shows CHRS's Inventory at $4.8 million in Q1 2026, $3.2 million in Q4 2025, and $2.0 million in Q3 2025.